Media Update: Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

https://ift.tt/GJmyQcW

Riliprubart one-year follow-up from phase 2 study underpin the potential as a first-in-class treatment in chronic inflammatory demyelinating polyneuropathy

from Sanofi - Aventis Groupe https://ift.tt/JGvkmjD
via IFTTT